Evaluating upadacitinib in the treatment of moderate-to-severe active ulcerative colitis: design, development, and potential position in therapy
M Napolitano, F D'Amico, E Ragaini… - Drug design …, 2023 - Taylor & Francis
Upadacitinib is a selective small molecule that inhibits Janus kinase (JAK) type 1. This
molecule is administrated orally and is currently approved for the treatment of rheumatoid …
molecule is administrated orally and is currently approved for the treatment of rheumatoid …
Patient-reported outcomes and disability are associated with histological disease activity in patients with ulcerative colitis: results from the APOLLO study
B Verstockt, L Pouillon, F Ballaux… - Journal of Crohn's …, 2023 - academic.oup.com
Abstract Background and Aims Treating beyond endoscopic remission, aiming for
histological remission, is an emerging target in ulcerative colitis [UC]. Patient-reported …
histological remission, is an emerging target in ulcerative colitis [UC]. Patient-reported …
Correlation of mucosal healing endpoints with long-term clinical and patient-reported outcomes in ulcerative colitis
Background We evaluated the clinical relevance of achieving histologic endoscopic
mucosal improvement (HEMI) and the more stringent target of histologic endoscopic …
mucosal improvement (HEMI) and the more stringent target of histologic endoscopic …